Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment

書誌詳細
主要な著者: Black, S, Wilcock, G, Zavitz, K, Hendrix, S, Swabb, E
フォーマット: Conference item
出版事項: 2008

類似資料